Treatment and recovery of Wagner 5 diabetic foot with Heberprot-P

Abstract

To improve the quality of life of diabetic patients suffering from diabetic foot ulcers, and trying to diminish or avoid major amputations among them, we tested the use of Heberprot-P® (epidermal growth factor) in seventy of those patients having Wagner’s grade 5 diabetic foot. The product was administered by intralesional injection, three times a week. Twelve patients (17.1%) were amputated and seven (9%) abandoned the treatment. Otherwise, twenty eight patients (40%) saved their legs, and 23(32.8%) are currently being administered with 75 µg of Heberprot-P (EGF), with good results. Until this moment, Heberprot-P constitutes an answer for diabetic patients having diabetic foot grade 5 in the Wagner scale.

Keywords

• ischemic diabetic foot
• human recombinant epidermal growth factor
• diabetic foot wagner 5
• wagner classification